Rosa C, Ghione S
CNR Institute of Clinical Physiology, Pisa, Italy.
Cardiovasc Drugs Ther. 1990 Jan;4 Suppl 1:133-5. doi: 10.1007/BF00053445.
An association between increased tolerance to pain and arterial hypertension has been reported in experimental animals and confirmed in humans. The underlying mechanisms remain elusive. We have recently reported that diuretics and beta-blocking treatment do not influence pain sensitivity, despite significant reductions in arterial blood pressure. In the present study, ketanserin was evaluated. As in previous work, pain perception was assessed with a tooth pulp tester. Ten hypertensive subjects were studied basally, after 15 days and after 3 months of ketanserin treatment (20 mg twice daily). Significant reductions in arterial blood pressure and of pain thresholds were observed, but no correlation between these changes occurred. These preliminary data indicate that, contrary to other hypotensive drugs, ketanserin tends to decrease or reverse the abnormality in pain modulation observed in hypertensive patients. The lack of a correlation between effects on blood pressure and pain sensitivity seems, however, to favor the hypothesis of two independent underlying mechanisms.
在实验动物中已报道疼痛耐受性增加与动脉高血压之间存在关联，并在人类中得到证实。其潜在机制仍不清楚。我们最近报道，利尿剂和β受体阻滞剂治疗尽管能显著降低动脉血压，但并不影响疼痛敏感性。在本研究中，对酮色林进行了评估。与之前的研究一样，使用牙髓测试仪评估疼痛感知。对10名高血压受试者在基线、酮色林治疗15天后和3个月后（每日两次，每次20mg）进行了研究。观察到动脉血压和疼痛阈值显著降低，但这些变化之间没有相关性。这些初步数据表明，与其他降压药物相反，酮色林倾向于减少或逆转高血压患者中观察到的疼痛调节异常。然而，血压影响与疼痛敏感性之间缺乏相关性似乎支持了两种独立潜在机制的假说。
